ZYME
$8.67
Zymeworks
$.18
2.12%
ZYME
Earnings Whisper ®
N/A
2nd Quarter June 2023
Consensus:  ($0.59)
Revenue:  $14.88 Mil
Monday
Aug 7
4:20 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ZYME reports earnings?
Beat
Meet
Miss

Where is ZYME's stock price going from here?
Up
Flat
Down
Stock chart of ZYME
Analysts
Summary of analysts' recommendations for ZYME
Score
Grade
Pivots
Resistance
$9.07
$8.88
$8.77

$8.58

Support
$8.47
$8.28
$8.17
Tweet
Growth
Description
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.